CTLA4 and cancer: Using analysis of outcome data from the CheckMate-067 trial, Oh, et al. 6 argue that the elevated costs associated with irAEs due to anti-CTLA-4 in combination with anti-PD-1 render it cost-ineffective despite the benefits of improved disease free survival in responsive cancers.